Keyphrases
Sunitinib
100%
Metastatic Renal Cell Carcinoma (mRCC)
87%
Single nucleotide Polymorphism
45%
Overall Survival
30%
Pharmacokinetics
29%
Genetic Polymorphism
25%
Progression-free Survival
25%
Tyrosine Kinase Inhibitor
19%
Pharmacogenetics
16%
Genetic Variants
16%
Induced Toxicity
15%
Cytochrome P450 3A4 (CYP3A4)
15%
SU12662
14%
Targeted Therapy
14%
Association Analysis
14%
Pharmacokinetics-pharmacodynamics (PK-PD)
13%
Clinical Outcomes
13%
Confidence Interval
12%
Inhibitor Formulations
12%
Clear-cell Metastatic Renal Cell Carcinoma
12%
Efficacy Outcomes
12%
Down Syndrome Cell Adhesion Molecule (DSCAM)
12%
CYP3A5 Polymorphism
12%
Age-appropriate Dosage Form
12%
Genome-wide Meta-analysis
12%
Collaborative Projects
12%
Induced Hypertension
12%
Population Modeling
12%
Tumor Biomarkers
12%
Pharmacogenomics
12%
Chemotherapy Toxicity
12%
Kinase Inhibitor
12%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
12%
Interleukin-13 (IL-13)
12%
PDLIM3
12%
ABCB1 Polymorphism
12%
Renal Cell
12%
Pediatric Cancer Patients
12%
Treatment Outcome
10%
Meta-analysis
9%
T Allele
8%
Pediatric Oncology
7%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
7%
Clinical Benefit
7%
ATP Binding Cassette Subfamily B Member 1 (ABCB1)
7%
CYP3A5
7%
Tumor
6%
Hypertension
6%
Potential Biomarkers
6%
Clinical Practice
6%
Pharmacology, Toxicology and Pharmaceutical Science
Sunitinib
99%
Kidney Metastasis
72%
Malignant Neoplasm
41%
Pharmacokinetics
32%
Overall Survival
31%
Biological Marker
28%
Progression Free Survival
26%
Protein Tyrosine Kinase Inhibitor
23%
Pharmacodynamics
21%
CYP3A4
17%
Pharmacogenetics
16%
Neoplasm
16%
Cytochrome P450 3A5
15%
Childhood Cancer
15%
N Deethylsunitinib
14%
Chemotherapy
12%
Pharmacogenomics
12%
Phosphotransferase Inhibitor
12%
Dosage Forms
12%
Cytotoxic T Lymphocyte Antigen 4
12%
Vasculotropin Receptor
6%
Renal Cell Carcinoma
6%
Biochemistry, Genetics and Molecular Biology
Sunitinib
74%
Single-Nucleotide Polymorphism
35%
Cancer Cell
26%
Overall Survival
25%
Genetic Polymorphism
25%
Pharmacokinetics
19%
Tyrosine Kinase Inhibitor
19%
Genetic Divergence
18%
Progression Free Survival
17%
CYP3A5
15%
Down Syndrome Cell Adhesion Molecule
12%
CTLA-4
12%
Pharmacogenomics
12%
Allele
9%
Pharmacodynamics
7%
Germline
6%
Germ Cell
6%
Drug Dose Reduction
6%
Pharmacogenetics
6%
Exome Sequencing
5%
Haplotype
5%
CYP3A4
5%